UTILITY IN FRENCH HEALTH-ECONOMIC OPINIONS- KEY LEARNINGS OF A RETROSPECTIVE ANALYSIS IN ONCOLOGY DRUGS
Author(s)
Galasso A1, Kandel M2, Borget I3
1CHATENAY MALABRY University, Chatenay Malabry, France, 2INSERM DR Paris 11, Villejuif, France, 3Univ Paris-Sud, Faculty of Pharmacy, GRADES, Châtenay-Malabry, France
OBJECTIVES: : In cost-utility analysis (CUA), main result is the ICER where effectiveness is expressed in QALY. Understanding utility valuation is important to assess ICER validity. The objective of this study was to describe how utility is implemented in oncology efficiency opinions (EO) and how it was evaluated by the National Authority of Health (HAS). METHODS: All the EO related to oncology drugs since 12/2014 by the HAS were reviewed. We collected utility values implemented in CUA, their data sources, as well as the methodological reservations related to utilities that were assessed by the HAS, by severity grade (minor/important/major). RESULTS: CONCLUSIONS: This analysis is the first to evaluate utility data in French EO. Most utility reservations were related to data validity and none was major. In the future, the use of utility data from the same source for PF and PD health states is recommended.
Conference/Value in Health Info
2018-11, ISPOR Europe 2018, Barcelona, Spain
Value in Health, Vol. 21, S3 (October 2018)
Code
PCN355
Topic
Patient-Centered Research
Topic Subcategory
Health State Utilities, Patient-reported Outcomes & Quality of Life Outcomes
Disease
Oncology